α-synuclein-induced synapse damage in cultured neurons is mediated by cholesterol-sensitive activation of cytoplasmic phospholipase A2

Biomolecules

Volumn 5, Issue 1, 2015, Pages 178-193

  Bate, Clive ^a   Williams, Alun ^b  

^a ROYAL VETERINARY COLLEGE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Alpha synuclein; Cholesterol; Parkinson s disease; Phospholipase A2; Platelet activating factor; Synapse; Synaptophysin

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA SYNUCLEIN; ARACHIDONYL TRIFLUOROMETHYL KETONE; CAFFEIC ACID; CHOLESTEROL; CYSTEINE STRING PROTEIN; CYTOSOLIC PHOSPHOLIPASE A2; GINKGOLIDE B; IBUPROFEN; METHYL ARACHIDONYL FLUOROPHOSPHONATE; NORDIHYDROGUAIARETIC ACID; PHOSPHOLIPASE A2 INHIBITOR; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE INHIBITOR; SYNAPTOPHYSIN; THROMBOCYTE ACTIVATING FACTOR; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; UNCLASSIFIED DRUG; NEUROPROTECTIVE AGENT; PROTEIN AGGREGATE; RECOMBINANT PROTEIN; SNCA PROTEIN, HUMAN;

ANIMAL CELL; ARTICLE; BRAIN SYNAPTOSOME; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; MOUSE; NERVE CELL; NERVE CELL CULTURE; NERVE INJURY; NONHUMAN; PROTEIN CONTENT; SYNAPSE; SYNAPSE DAMAGE; SYNAPTOGENESIS; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CULTURE; CHEMISTRY; DRUG EFFECTS; ENZYME ACTIVATION; ENZYMOLOGY; HUMAN; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION;

ALPHA-SYNUCLEIN; ANIMALS; CELLS, CULTURED; CHOLESTEROL; CYCLOOXYGENASE INHIBITORS; ENZYME ACTIVATION; HUMANS; MICE; NEURONS; NEUROPROTECTIVE AGENTS; PHOSPHOLIPASES A2, CYTOSOLIC; PLATELET ACTIVATING FACTOR; PROTEIN AGGREGATES; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; SYNAPSES;

EID: 84989323110     PISSN: None     EISSN: 2218273X     Source Type: Journal    
DOI: 10.3390/biom5010178     Document Type: Article

References (53)

1. Poewe, W. Non-motor symptoms in Parkinson’s disease. Eur. J. Neurol. 2008, 15, 14–20.
2. Aarsland, D.; Andersen, K.; Larsen, J. P.; Lolk, A.; Kragh-Sorensen, P. Prevalence and characteristics of dementia in Parkinson disease: An 8-year prospective study. Arch. Neurol. 2003, 60, 387–392.
3. McKeith, I. G.; Dickson, D. W.; Lowe, J.; Emre, M.; O’Brien, J.T.; Feldman, H.; Cummings, J.; Duda, J. E.; Lippa, C.; Perry, E. K.; et al. Diagnosis and management of dementia with Lewy bodies: Third report of the DLB Consortium. Neurology 2005, 65, 1863–1872.
4. Bonini, N. M.; Giasson, B. I. Snaring the function of alpha-synuclein. Cell 2005, 123, 359–361.
5. Cabin, D. E.; Shimazu, K.; Murphy, D.; Cole, N.B.; Gottschalk, W.; McIlwain, K. L.; Orrison, B.; Chen, A.; Ellis, C. E.; Paylor, R.; et al. Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein. J. Neurosci. 2002, 22, 8797–8807.
6. Clayton, D. F.; George, J. M. The synucleins: A family of proteins involved in synaptic function, plasticity, neurodegeneration and disease. Trends Neurosci. 1998, 21, 249–254.
7. Kazantsev, A. G.; Kolchinsky, A. M. Central role of alpha-synuclein oligomers in neurodegeneration in Parkinson disease. Arch. Neurol. 2008, 65, 1577–1581.
8. Kramer, M. L.; Schulz-Schaeffer, W. J. Presynaptic a-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies. J. Neurosci. 2007, 27, 1405–1410.
9. Lee, V.M.Y.; Trojanowski, J.Q. Mechanisms of Parkinson’s disease linked to pathological a-synuclein: New targets for drug discovery. Neuron 2006, 52, 33–38.
10. Desplats, P.; Lee, H. J.; Bae, E. J.; Patrick, C.; Rockenstein, E.; Crews, L.; Spencer, B.; Masliah, E.; Lee, S. J. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of a-synuclein. Proc. Natl. Acad. Sci. USA 2009, 106, 13010–13015.
11. Brundin, P.; Melki, R.; Kopito, R. Prion-like transmission of protein aggregates in neurodegenerative diseases. Nat. Rev. Mol. Cell Biol. 2010, 11, 301–307.
12. Braak, H.; del Tredici, K.; Rub, U.; de Vos, R. A.; Jansen Steur, E. N.; Braak, E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol. Aging 2003, 24, 197–211.
13. Galvin, J.E.; Uryu, K.; Lee, V.M.; Trojanowski, J.Q. Axon pathology in Parkinson’s disease and Lewy body dementia hippocampus contains alpha-, beta-, and gamma-synuclein. Proc. Natl. Acad. Sci. USA 1999, 96, 13450–13455.
14. Chung, C. Y.; Koprich, J. B.; Siddiqi, H.; Isacson, O. Dynamic changes in presynaptic and axonal transport proteins combined with striatal neuroinflammation precede dopaminergic neuronal loss in a rat model of AAV alpha-synucleinopathy. J. Neurosci. 2009, 29, 3365–3373.
15. Bate, C.; Gentleman, S.; Williams, A. a-synuclein induced synapse damage is enhanced by amyloid-b1–42. Mol. Neurodegener. 2010, 5, doi:10.1186/1750-1326-5-55.
16. Bate, C.; Tayebi, M.; Williams, A. Phospholipase A2 inhibitors protect against prion and Ab mediated synapse degeneration. Mol. Neurodegener. 2010, doi:10.1186/1750-1326-5-13.
17. Sze, C. I.; Troncoso, J. C.; Kawas, C.; Mouton, P.; Price, D. L.; Martin, L. J. Loss of the presynapticvesicle protein synaptophysin in hippocampus correlates with cognitive decline in Alzheimer disease. J. Neuropath Exp. Neurol. 1997, 56, 933–944.
18. Terry, R. D.; Masliah, E.; Salmon, D. P.; Butters, N.; deTeresa, R.; Hill, R.; Hansen, L.A.; Katzman, R. Physical basis of cognitive alterations in Alzheimer’s disease: Synapse loss is the major correlate of cognitive impairment. Ann. Neurol. 1991, 30, 572–580.
19. Bate, C.; Williams, A. Amyloid-b-induced synapse damage is mediated via cross-linkage of the cellular prion protein. J. Biol. Chem. 2011, 286, 37955–37963.
20. Francescangeli, E.; Domanska-Janik, K.; Goracci, G. Relative contribution of the de novo and remodelling pathways to the synthesis of platelet-activating factor in brain areas and during ischemia. J. Lipid Mediat. Cell Signal. 1996, 14, 89–98.
21. Bate, C.; Tayebi, M.; Williams, A. Ginkgolides protect against amyloid-b1–42-mediated synapse damage in vitro. Mol. Neurodegener. 2008, doi:10.1186/1750-1326-3-1.
22. Teixeira, M. M.; al Rashed, S.; Rossi, A. G.; Hellewell, P. G. Characterization of the prostanoid receptors mediating inhibition of PAF-induced aggregation of guinea-pig eosinophils. Br. J. Pharmacol. 1997, 121, 77–82.
23. Sugimoto, Y.; Narumiya, S. Prostaglandin E receptors. J. Biol. Chem. 2007, 282, 11613–11617.
24. Nalefski, E. A.; Sultzman, L. A.; Martin, D. M.; Kriz, R. W.; Towler, P. S.; Knopf, J.L.; Clark, J. D. Delineation of two functionally distinct domains of cytosolic phospholipase A2, a regulatory Ca2+-dependent lipid-binding domain and a Ca2+-independent catalytic domain. J. Biol. Chem. 1994, 269, 18239–18249.
25. Crick, D. C.; Suders, J.; Kluthe, C. M.; Andres, D. A.; Waechter, C. J. Selective inhibition of cholesterol biosynthesis in brain cells by squalestatin 1. J. Neurochem. 1995, 65, 1365–1373.
26. Bate, C.; Williams, A. Squalestatin protects neurons and reduces the activation of cytoplasmic phospholipase A2 by Ab1–42. Neuropharmacology 2007, 53, 222–231.
27. Farooqui, A. A.; Horrocks, L. A. Phospholipase A2-generated lipid mediators in the brain: The good, the bad, and the ugly. Neuroscientist 2006, 12, 245–260.
28. Farooqui, A. A.; Ong, W. Y.; Horrocks, L. A. Inhibitors of brain phospholipase A2 activity: Their neuropharmacological effects and therapeutic importance for the treatment of neurologic disorders. Phamacol. Rev. 2006, 58, 591–620.
29. Malaplate-Armand, C.; Florent-Bechard, S.; Youssef, I.; Koziel, V.; Sponne, I.; Kriem, B.; Leininger-Muller, B.; Olivier, J. L.; Oster, T.; Pillot, T. Soluble oligomers of amyloid-b peptide induce neuronal apoptosis by activating a cPLA2-dependent sphingomyelinase-ceramide pathway. Neurobiol. Dis. 2006, 23, 178–189.
30. Kriem, B.; Sponne, I.; Fifre, A.; Malaplate-Armand, C.; Lozac’h-Pillot, K.; Koziel, V.; Yen-Potin, F.T.; Bihain, B.; Oster, T.; Olivier, J. L.; et al. Cytosolic phospholipase A2 mediates neuronal apoptosis induced by soluble oligomers of the amyloid-
31. Klivenyi, P.; Beal, M. F.; Ferrante, R. J.; Andreassen, O. A.; Wermer, M.; Chin, M.R.; Bonventre, J.V. Mice deficient in group IV cytosolic phospholipase A2 are resistant to MPTP neurotoxicity. J. Neurochem. 1998, 71, 2634–2637.
32. Sanchez-Mejia, R.O.; Newman, J. W.; Toh, S.; Yu, G. Q.; Zhou, Y.; Halabisky, B.; Cisse, M.; Scearce-Levie, K.; Cheng, I. H.; Gan, L.; et al. Phospholipase A2 reduction ameliorates cognitive deficits in a mouse model of Alzheimer’s disease. Nat. Neurosci. 2008, 11, 1311–1318.
33. Sun, G. Y.; Xu, J.; Jensen, M. D.; Simonyi, A. Phospholipase A2 in the central nervous system: Implications for neurodegenerative diseases. J. Lipid Res. 2004, 45, 205–213.
34. Bellizzi, M. J.; Lu, S. M.; Masliah, E.; Gelbard, H. A. Synaptic activity becomes excitotoxic in neurons exposed to elevated levels of platelet-activating factor. J. Clin. Investig. 2005, 115, 3185–3192.
35. Rojas, P.; Serrano-García, N.; Mares-Sámano, J.J.; Medina-Campos, O.N.; Pedraza-Chaverri, J.; Ögren, S.O. EGb761 protects against nigrostriatal dopaminergic neurotoxicity in 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice: Role of oxidative stress. Eur. J. Neurosci. 2008, 28, 41–50.
36. Rojas, P.; Montes, P.; Rojas, C.; Serrano-García, N.; Rojas-Castañeda, J.C. Effect of a phytopharmaceutical medicine, Ginko biloba extract 761, in an animal model of Parkinson’s disease: Therapeutic perspectives. Nutrition 2012, 28, 1081–1088.
37. Chen, C.; Bazan, N.G. Endogenous PGE2 regulates membrane excitability and synaptic transmission in hippocampal CA1 pyramidal neurons. J. Neurphysiol. 2005, 93, 929–941.
38. Maxfield, F. R.; Tabas, I. Role of cholesterol and lipid organization in disease. Nature 2005, 438, 612–621.
39. Dolga, A. M.; Culmsee, C.; de Lau, L.; Winter, Y.; Oertel, W.H.; Luiten, P.G.M.; Eisel, U.L.M. Statins—Increasing or reducing the risk of Parkinson’s disease? Exp. Neurol. 2011, 228, 1–4.
40. Hu, G.; Antikainen, R.; Jousilahti, P.; Kivipelto, M.; Tuomilehto, J. Total cholesterol and the risk of Parkinson disease. Neurology 2008, 70, 1972–1979.
41. Koob, A. O.; Ubhi, K.; Paulsson, J. F.; Kelly, J.; Rockenstein, E.; Mante, M.; Adame, A.; Masliah, E. Lovastatin amelioratesa-synuclein accumulation and oxidation in transgenic mouse models of a-synucleinopathies. Exp. Neurol. 2010, 221, 267–274.
42. Wahner, A. D.; Bronstein, J. M.; Bordelon, Y. M.; Ritz, B. Statin use and the risk of Parkinson disease. Neurology 2008, 70, 1418–1422.
43. Wolozin, B.; Kellman, W.; Ruosseau, P.; Celesia, G.G.; Siegel, G. Decreased prevalence of alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch. Neurol. 2000, 57, 1439–1443.
44. Samii, A.; Carleton, B. C.; Etminan, M. Statin use and the risk of Parkinson disease: A nested case control study. J. Clin. Neurosci. 2008, 15, 1272–1273.
45. Becker, C.; Meier, C.R. Statins and the risk of Parkinson disease: An update on the controversy. Expert Opin. Drug Saf. 2009, 8, 261–271.
46. Baxter, A.; Fitzgerald, B. J.; Hutson, J. L.; McCarthy, A.D.; Motteram, J.M.; Ross, B.C.; Sapra, M.; Snowden, M.A.; Watson, N.S.; Williams, R.J. Squalestatin 1, a potent inhibitor of squalene synthase, which lowers serum cholesterol in vivo. J. Biol. Chem. 1992, 267, 11705–11708.
47. Pike, L. J. Lipid rafts: Heterogeneity on the high seas. Biochem. J. 2004, 378, 281–292.
48. Simons, K.; Toomre, D. Lipid rafts and signal transduction. Nat. Rev. Mol. Cell Biol. 2000, 1, 31–39.
49. Graziani, A.; Bricko, V.; Carmignani, M.; Graier, W.F.; Groschner, K. Cholesterol- and caveolin-rich membrane domains are essential for phospholipase A2-dependent EDHF formation. Cardiovasc. Res. 2004, 64, 234–242.
50. Bate, C.; Tayebi, M.; Williams, A. Sequestration of free cholesterol in cell membranes by prions correlates with cytoplasmic phospholipase A2 activation. BMC Biol. 2008, doi:10.1186/1741-7007-6-8.
51. Thais, M. E.; Carqueja, C. L.; Santos, T. G.; Silva, R. V.; Stroeh, E.; Machado, R. S.; Wahlheim, D. O.; Bianchin, M. M.; Sakamoto, A. C.; Brentani, R. R.; et al. Synaptosomal glutamate release and uptake in mice lacking the cellular prion protein. Brain Res. 2006, 1075, 13–19.
52. London, E.; Brown, D. A. Insolubility of lipids in Triton X-100: Physical origin and relationship to sphingolipid/cholesterol membrane domains (rafts). Biochim. Biophys. Acta 2000, 1508, 182–195.
53. Bate, C.; Williams, A. Monoacylated cellular prion protein modifies cell membranes, inhibits cell signaling and reduces prion formation. J. Biol. Chem. 2011, 286, 8752–8758.